Acerca de este artículo
Categoría del artículo: Research Paper
Publicado en línea: 22 abr 2020
Páginas: 3 - 17
Recibido: 10 ene 2020
Aceptado: 25 mar 2020
DOI: https://doi.org/10.2478/jdis-2020-0002
Palabras clave
© 2020 Jian Qin, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Figure 1
Figure 2
Major relationships types and patterns between knowledge nodes observed in the sample publications_
| Relationship | Pattern | Example |
|---|---|---|
| has-biomarker | ||
| is-driver-of | ||
| targets | ||
| has-role-of |
Similarities in goals, methods, and functions between KO and KR paradigms_
| Paradigm | Goals | Methods | Functions | |
|---|---|---|---|---|
| KO | Integration | Organize the knowledge universe | Categorize, classify generalize, synthesize | Represent knowledge in publications and organize knowledge about nature and/or society |
| Disintegration | Organize the knowledge in a domain | Categorize, classify, generalize, synthesize, model | Represent knowledge in data and publications in a domain | |
| KR | Production rules | Represent knowledge in condition-action pairs to solve problems | Use forward chaining algorithms to execute condition-action pairs | Represent fragmentary knowledge in entity-attribute-value (triple) format |
| Semantic networks and frames | Represent semantic relations between concepts | Express semantic relations in triples | Connect knowledge nodes through attributes or slots to form a knowledge graph | |
| First-order logic | Formalize qualifier construction in natural language | Express declarative propositions using the first-order logic syntax and semantics | Produce a set of axioms for reasoning |
Examples of knowledge nodes derived from the sample publications_
| Category | Atomic level (name of things) | Concept level | Cluster level |
|---|---|---|---|
| Gene | Her2, BRCA1, BRCA2, EGFR | Oncogenes | EGFR mutations in lung cancer |
| Disease | Non-squamous carcinoma, squamous cell carcinoma | Non-small cell lung cancer | Lung cancer |
| Drug | Pertumzumab, Lmatinib, Crizotinib | Tyrosine kinase inhibitor | Oncogene de-addiction |